Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Technology / Medera SRD-002 HFpEF Trial Advances
Tech clinical trial update

Medera SRD-002 HFpEF Trial Advances

Analysis based on 6 articles · First reported Jun 25, 2026 · Last updated Jun 25, 2026

Sentiment
70
Attention
6
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive recommendation from the independent Data Monitoring Committee for Moderna's SRD-002 gene therapy in the MUSIC-HFpEF trial is a significant de-risking event for Moderna. This news is likely to boost investor confidence in Moderna's stock, as it signals progress towards regulatory approval and addresses a large unmet medical need in cardiovascular medicine.

Biotechnology Pharmaceuticals
Event Summary

Moderna, a clinical-stage biotechnology company, announced that an independent Data Monitoring Committee (DMC) recommended the continued advancement of its MUSIC-HFpEF clinical trial for SRD-002, a gene therapy for heart failure with preserved ejection fraction (HFpEF), without protocol modification. The DMC found no safety concerns after reviewing accumulated clinical data, including long-term follow-up from both dose cohorts. This positive outcome supports Moderna's preparations for discussions with the United States — Food and Drug Administration (FDA) regarding the next randomized stage of development. Additionally, the DMC also reviewed Moderna's MUSIC-HFrEF Phase 1/2a clinical trial data, identifying no safety concerns, with the randomized MUSIC-HFrEF Phase 2b trial currently ongoing. Ronald Iu, CEO of Moderna, highlighted the importance of this independent review as a clinical and regulatory de-risking milestone.

Entities Involved
stock
Moderna
Moderna is the clinical-stage biotechnology company developing the gene therapy SRD-002 for heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The positive DMC recommendation for its MUSIC-HFpEF trial and the ongoing MUSIC-HFrEF trial are significant milestones for the company, supporting its continued advancement in cardiovascular gene therapy.
Importance 100.0 Sentiment 75.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration is the regulatory body with whom Moderna will discuss the next randomized stage of development for SRD-002, making its involvement crucial for the therapy's future.
Importance 70.0 Sentiment 0.0
per
Ronald Iu
Ronald Iu is the CEO and Founder of Moderna, providing commentary on the positive outcome of the independent DMC review and the significance of the results for the company's HFpEF program.
Importance 60.0 Sentiment 0.0
per
Roger J. Hajjar
Roger J. Hajjar is the President and Chief Medical Officer of Moderna, emphasizing the encouraging support for the safety profile of Moderna's cardiovascular gene therapy platform.
Importance 50.0 Sentiment 0.0
ngo
American Heart Association
The American Heart Association Scientific Sessions 2025 was where previous positive data from Moderna's Cohort A patients were reported, providing a platform for disseminating early clinical findings.
Importance 20.0 Sentiment 0.0
Relationships
Moderna related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.